Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H32O3 |
Molecular Weight | 344.4877 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]3([H])[C@@]2([H])C[C@H](C)C4=CC(=O)CC[C@]34C
InChI
InChIKey=GZENKSODFLBBHQ-ILSZZQPISA-N
InChI=1S/C22H32O3/c1-12-9-15-17-6-5-16(13(2)23)22(17,4)11-19(25)20(15)21(3)8-7-14(24)10-18(12)21/h10,12,15-17,19-20,25H,5-9,11H2,1-4H3/t12-,15-,16+,17-,19-,20+,21-,22+/m0/s1
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6336597 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | HMS Approved UseHMS (medrysone ophthalmic suspension) is a synthetic corticosteroid with topical anti-inflammatory activity. Corticoidsteroids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as well as capillary proliferation, deposition of collagen, and scar formation. HMS (medrysone ophthalmic suspension) has less anti-inflammatory potency than 0.1% dexamethasone. Launch Date1969 |
|||
Primary | HMS Approved UseHMS (medrysone ophthalmic suspension) is a synthetic corticosteroid with topical anti-inflammatory activity. Corticoidsteroids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as well as capillary proliferation, deposition of collagen, and scar formation. HMS (medrysone ophthalmic suspension) has less anti-inflammatory potency than 0.1% dexamethasone. Launch Date1969 |
|||
Primary | HMS Approved UseHMS (medrysone ophthalmic suspension) is a synthetic corticosteroid with topical anti-inflammatory activity. Corticoidsteroids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as well as capillary proliferation, deposition of collagen, and scar formation. HMS (medrysone ophthalmic suspension) has less anti-inflammatory potency than 0.1% dexamethasone. Launch Date1969 |
Doses
Dose | Population | Adverse events |
---|---|---|
1 drop 12 times / day multiple, ophthalmic Dose: 1 drop, 12 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 12 times / day Sources: |
unhealthy, 44 years |
Disc. AE: Redness of eyelid, Swelling of eyelid... AEs leading to discontinuation/dose reduction: Redness of eyelid (1 patient) Sources: Swelling of eyelid (1 patient) Itching eyes (severe, 1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Redness of eyelid | 1 patient Disc. AE |
1 drop 12 times / day multiple, ophthalmic Dose: 1 drop, 12 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 12 times / day Sources: |
unhealthy, 44 years |
Swelling of eyelid | 1 patient Disc. AE |
1 drop 12 times / day multiple, ophthalmic Dose: 1 drop, 12 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 12 times / day Sources: |
unhealthy, 44 years |
Itching eyes | severe, 1 patient Disc. AE |
1 drop 12 times / day multiple, ophthalmic Dose: 1 drop, 12 times / day Route: ophthalmic Route: multiple Dose: 1 drop, 12 times / day Sources: |
unhealthy, 44 years |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C521
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
||
|
NDF-RT |
N0000175450
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
||
|
WHO-VATC |
QS01BA08
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
||
|
NDF-RT |
N0000175576
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
||
|
WHO-ATC |
S01BA08
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1662
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | |||
|
DTXSID6045371
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | |||
|
100000081994
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201173
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | |||
|
D2UFC189XF
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | |||
|
220-208-7
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | |||
|
C47598
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | |||
|
247839
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | |||
|
C100283
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | |||
|
2668-66-8
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | |||
|
7086
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | |||
|
SUB08701MIG
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | |||
|
2039
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | |||
|
m7135
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | Merck Index | ||
|
D2UFC189XF
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | |||
|
63278
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | |||
|
29439
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | RxNorm | ||
|
MEDRYSONE
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY | |||
|
DB00253
Created by
admin on Sat Dec 16 16:00:49 GMT 2023 , Edited by admin on Sat Dec 16 16:00:49 GMT 2023
|
PRIMARY |
ACTIVE MOIETY